The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Results of the APHINITY Trial in HER2-Positive Breast Cancer

Denise Yardley, MD
Published Online: 6:33 PM, Tue June 6, 2017

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the APHINITY trial, which compared chemotherapy plus trastuzumab (Herceptin) plus placebo versus chemotherapy plus trastuzumab plus pertuzumab (Perjeta) as adjuvant therapy in patients with HER2-positive early breast cancer.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.